F 18 pylarify radiopharmaceutical. Base IDIQ contract.
Active Awarded Last action
- Contract number
- 36C24626N0284
- Awardee
-
Progenics Pharmaceuticals Inc. UEI YLYKVRPCTCR3 Part of Lantheus Holdings, Inc.
- Awarding agency
-
Veterans Integrated Service Network 6
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $1,497,619
Award facts
- Contract value 100% obligated
- $1,497,618.80 Current and potential, with all options
- Completion date 89% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Not Competed under SAP Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- North Billerica, Billerica, MA 01862, USA
Award details come from SAM.gov/FPDS.
About this award
Progenics Pharmaceuticals Inc., a division of Lantheus Medical Imaging, Inc., received a delivery order contract valued at $1.50M from the Department of Veterans Affairs (VA), Veterans Integrated Service Network 6, effective January 1, 2025, through December 31, 2026. The contract, issued on a firm fixed-price basis with no set-aside designation, calls for the supply of PYLARIFY (piflufolastat F-18), a positron emission tomography (PET) diagnostic imaging agent used to detect and localize prostate cancer. The product will be delivered to the VA facility in North Billerica, Massachusetts, and represents a child delivery order issued under the company's broader Indefinite Delivery Vehicle relationships with the VA through the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB).
This award reflects the VA's ongoing procurement of critical radiopharmaceutical imaging solutions to support diagnostic medicine programs across its medical centers. Progenics Pharmaceuticals, under parent company Lantheus Holdings, Inc., has established itself as a primary supplier of specialized nuclear medicine products to federal healthcare providers, including the VA, Defense Health Agency, and National Institutes of Health. The company maintains substantial IDV agreements with federal agencies, with potential values ranging up to $290M, enabling efficient task order issuance for radiopharmaceuticals that support comprehensive cancer detection and diagnostic imaging capabilities across military and veteran healthcare systems nationwide.
Quick answers
Who was awarded contract 36C24626N0284?
36C24626N0284 was awarded to Progenics Pharmaceuticals Inc. by Veterans Integrated Service Network 6 (Veterans Health Administration) on January 1, 2025.
How much is contract 36C24626N0284 worth?
The government has obligated $1,497,619 on 36C24626N0284.
Is contract 36C24626N0284 an order under another contract?
Yes. 36C24626N0284 is a delivery order under 36C24625D0023, an indefinite delivery contract.
Was contract 36C24626N0284 competed?
The extent of competition for 36C24626N0284 was not competed under sap.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award